Drug Profile


Alternative Names: APL2

Latest Information Update: 22 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apellis Pharmaceuticals
  • Class Antianaemics; Cyclic peptides; Eye disorder therapies
  • Mechanism of Action Complement C3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune haemolytic anaemia; Dry age-related macular degeneration; Glomerulonephritis; IgA nephropathy; Lupus nephritis; Membranous glomerulonephritis
  • Phase I/II Wet age-related macular degeneration
  • Phase I Ischaemia; Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 19 Mar 2018 Updated efficacy data from the phase II FILLY trial in Dry age-related macular degeneration released by Apellis Pharmaceuticals
  • 24 Jan 2018 Phase-I/II clinical trials in Wet age-related macular degeneration (In the elderly, In adults) in USA (Intravitreous) (NCT03465709)
  • 22 Jan 2018 Phase-II clinical trials in Glomerulonephritis (C3 glomerulonephritis and dense deposit disease) in USA (SC) (NCT03453619)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top